Kamada vs Ligand Pharmaceuticals
KMDA and LGND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KMDA and LGND compare
Kamada grew revenue faster over the last twelve months (13.2% versus 1.0% for Ligand Pharmaceuticals).
Ligand Pharmaceuticals scores higher on the StockData Score (6 against 5 for Kamada), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KMDA | LGND |
|---|---|---|
| Size and price | ||
| Market cap | – | $6.2B |
| Share price | $8.09 | $308.79 |
| Change, 1 year | 11.1% | 50.2% |
| Change, 5 years | 44.5% | 90.7% |
| Beta (5Y) | 0.76 | 1.30 |
| Employees | 393 | 47 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 135× |
| P/S | – | 24.3× |
| P/B | – | 6.4× |
| EV/EBITDA | – | 113× |
| P/FCF | – | 68.2× |
| FCF yield | – | 1.5% |
| Fair value | – | $55.48 |
| Margin of safety | – | −457% |
| Growth | ||
| Revenue growth (TTM) | 13.2% (better) | 1.0% |
| Revenue growth, 5Y average | 6.3% | 10.4% (better) |
| Net income growth (TTM) | – | 5.9% |
| EPS growth (TTM) | – | 18.7% |
| EPS growth, 5Y average | −1.6% | – |
| Profitability | ||
| Gross margin | 40.8% | – |
| Operating margin | 14.5% (better) | 10.1% |
| Net margin | – | 20.3% |
| FCF margin | – | 35.7% |
| Return on equity | – | 5.4% |
| Return on invested capital | – | 2.6% |
| Financial health | ||
| Debt / equity | – | 1.17 |
| Net debt / EBITDA | −0.54 | 11.26 (better) |
| Interest coverage | 26.8× (better) | 3.1× |
| Current ratio | 4.06 (better) | 1.22 |
| Altman Z-score | – | 3.46 |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 8.6% | 113% |
| Held by insiders | 45.3% | 2.6% |
| Insider net buying, 12 months | −$1.7M (better) | −$35.7M |
| Short interest, % of float | 0.53% | – |
Go deeper
- KMDA stock overview
- KMDA income statement
- KMDA valuation and score
- LGND stock overview
- LGND income statement
- LGND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.